Therefore, more enhanced hrACE2 and antiviral agent combination regimens for COVID-19 treatment experiments are required in primates or human subjects regarding recombinant ACE2 and its effect on SARS-CoV-2. The gene discussed is ACE2; the disease is COVID-19.